POZ January-February 2015

POZ January-February 2015

In every issue, you’ll find the hottest topics of interest to our readers along with cutting-edge health information.

Also Available On:



POZ Magazine

Straight Talk

Advocating for HIV peer education programs in and out of prison

Burden of Proof

Is criminalizing HIV ever a good idea?

From the Editor

Philadelphia Freedom

According to the CDC, an estimated 1 in 7 persons living with HIV pass through a correctional facility each year. 


POZ Magazine

Letters-January/February 2015

In the article “PrEP and Prejudice” (October/November 2014), Benjamin Ryan wrote about Truvada’s use as pre-exposure prophylaxis (PrEP)...


Vertical Challenge

The Elizabeth Glaser Pediatric AIDS Foundation believes ending mother-to-child transmission is closer than ever.

POZ Planet

AIDS and Ebola

History repeats itself in this tale of two global epidemics.

Laverne Cox

Say What? Laverne Cox Edition

At the 2014 United States Conference on AIDS, Laverne Cox gave a speech that was simultaneously entertaining, informative and very intimate.

POZ Magazine

Gender Studies

Iris House clients see excellent viral suppression rates. Here’s why.

POZ Magazine

Evel Dick’s Most Unusual Diagnosis Story

There’s never a good time to learn you have HIV. But imagine getting the news while filming the reality show Big Brother. That’s what happened...


My Refuge

Actor and writer Bruce Ward shares how going (or sometimes just trying to go) to the gym helps him cope as a long-term survivor.

Care and Treatment

POZ Magazine

FDA OKs New Boosting Agent

The U.S. Food and Drug Administration (FDA) has approved Gilead Sciences’ Tybost (cobicistat) as a boosting agent to raise the drug levels..

POZ Magazine

Vitekta Gets FDA Approval

The U.S. Food and Drug Administration (FDA) has approved Gilead Sciences’ integrase strand transfer inhibitor Vitekta (elvitegravir) for HIV-p...

POZ Magazine

New Form of Viread Is Kinder to the Kidneys

Gilead Sciences has applied to the U.S. Food and Drug Administration (FDA) for approval of the first single-pill combination tablet to...

POZ Magazine

New HIV Antibody Target Could Have Many Benefits

National Institutes of Health (NIH) researchers have found a new site on HIV’s surface that is vulnerable to a powerful broadly neutralizing a...

Research Notes

POZ Magazine

Prevention: Americans Adhered Well to PrEP in iPrEx

A new analysis of the global iPrEx study, which proved Truvada’s (tenofovir/emtricitabine) efficacy as pre-exposure prophylaxis (PrEP), found...

POZ Magazine

Treatment: Hope for ARV-Free Treatment

New laboratory research has shown that what are known as broadly neutralizing antibodies (BNAs) can block HIV from entering or replicating ins...

POZ Magazine

Cure: What Cured the Berlin Patient?

A small primate study has suggested that the radiation element of the leukemia treatment that Timothy Ray Brown (a.k.a. the Berlin Patient) re...

POZ Magazine

Concerns: HIV Not on Young Gays’ Radar

A new nationally representative survey of American gay and bisexual men paints the image of a population largely unconcerned about HIV

POZ Survey Says

POZ Magazine

Online Chatter

According to Nielsen’s Social Media Report, Americans spend nearly 25 percent of their time on social networks and blogs.

POZ Heroes

POZ Magazine

Justice For All

Venton Jones actually got involved in AIDS work a year before he was diagnosed with HIV. 


Hot topics